132 related articles for article (PubMed ID: 3652060)
1. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
Wilson K; Shelley W; Belch A; Brandes L; Bergsagel D; Klimo P; White D; Willan A
Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060
[TBL] [Abstract][Full Text] [Related]
2. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone.
Brandes LJ; Israels LG
Cancer Treat Rep; 1982 Jun; 66(6):1413-5. PubMed ID: 6177412
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
6. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Bonnet JD; Alexanian R; Salmon SE; Haut A; Dixon DO
Cancer Treat Rep; 1984 Mar; 68(3):481-5. PubMed ID: 6200220
[TBL] [Abstract][Full Text] [Related]
7. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
[No Abstract] [Full Text] [Related]
8. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
[TBL] [Abstract][Full Text] [Related]
9. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
[TBL] [Abstract][Full Text] [Related]
10. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Wutke K; Anger G
Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
12. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
Hansen OP; Clausen NA; Drivsholm A; Laursen B
Scand J Haematol; 1985 Nov; 35(5):518-24. PubMed ID: 3911373
[TBL] [Abstract][Full Text] [Related]
13. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
[No Abstract] [Full Text] [Related]
14. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
15. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma].
Hara M; Nakamura T; Fujii Y
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1338-41. PubMed ID: 3579331
[TBL] [Abstract][Full Text] [Related]
16. [Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
Raya Sánchez JM; González Brito G; Marsá Vila L; Brito Barroso ML; Hernández Nieto L
Sangre (Barc); 1991 Oct; 36(5):434-5. PubMed ID: 1816642
[No Abstract] [Full Text] [Related]
17. [Possibility of using interferon in the treatment of multiple myeloma].
Piatkowska-Jakubas B; Skotnicki AB; Blicharski J
Przegl Lek; 1988; 45(10):747-50. PubMed ID: 3072590
[No Abstract] [Full Text] [Related]
18. [Acute ischemia and heart failure during cyclic chemotherapy in a patient with plasmocytic myeloma].
Drzewoski J; Olszańska-Skorek T; Urbańska-Ryś H; Kończalik P; Krykowski E
Pol Tyg Lek; 1990 Dec 17-31; 45(51-52):1056-8. PubMed ID: 2098746
[No Abstract] [Full Text] [Related]
19. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
Cohen HJ; Bartolucci AA; Forman WB; Silberman HR
J Clin Oncol; 1986 Jun; 4(6):888-99. PubMed ID: 3519879
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of a nitrosurea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma (author's transl)].
Bezares R; Bomchil G; Saslavsky J; Pavlovsky S; Curutchet M; Quiroga Micheo E; Macchi A; Musso A; Suárez A; Pizzolato M
Sangre (Barc); 1979; 24(3):241-51. PubMed ID: 472966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
